Treace Medical Concepts, Inc. (TMCI)

Over the past six months, Treace Medical Concepts' stock experienced a substantial decline of 68.87%, falling from $7.87 to $2.45 per share. In Q3 2025, the company reported EPS of -$0.26 and quarterly revenue of $50.21 million, surpassing consensus estimates. Preliminary Q4 2025 revenue was announced at $62.1 million to $62.5 million, representing an approximate 9% decrease compared to the same period in 2024. Preliminary full-year 2025 revenue rose modestly by roughly 2% to a range of $212.3 million to $212.7 million. Analyst ratings indicate a current Wall Street consensus of "hold," with an average 12-month price target of $4.64. James T. Treace retired from the Board on April 2, 2025, and John T. Treace was appointed Chairman of the Board.

Treace Medical Concepts experiences demand seasonality for its products and services, anticipating seasonal strength particularly in the fourth quarter due to patient deductibles. Growth rates are expected to accelerate sequentially in Q3 and Q4, with the most substantial growth contribution anticipated in Q4. Q2 growth is generally expected to be consistent with the prior year's Q2.

Treace Medical Concepts, Inc. (TMCI) is a medical technology company based in Ponte Vedra Beach, Florida, that specializes in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. The company focuses on advancing the standard of care for the surgical management of bunion and related midfoot deformities. Its major products include the Lapiplasty® 3D Bunion Correction® System, which corrects bunion deformities in all three planes; the Adductoplasty® Midfoot Correction System, designed for surgical correction of midfoot deformities; the Hammertoe PEEK Fixation System, which addresses hammertoe, claw toe, and mallet toe deformities; Minimally Invasive Osteotomy Systems, including the Nanoplasty™ and Percuplasty™ systems; the SpeedMTP™ Rapid Compression Implant, used for big toe joint fusions; and the SpeedPlate™ Rapid Compression Implants, a fixation platform for various foot fusion procedures.

Treace Medical Concepts primarily serves orthopedic surgeons and podiatrists across the United States.

Treace Medical Concepts emphasizes surgeon education and support to ensure the effective adoption of its technologies. The company's mission to advance the standard of care for bunion and related midfoot deformities, coupled with its focus on rigorous research, development, and clinical validation, contributes to its reputation within the medical device industry. The successful development and broad release of a full suite of bunion solutions, including new systems like Nanoplasty, Percuplasty 3D MIS osteotomy, and SpeedMTP great-toe fusion, have been met with high surgeon enthusiasm in limited releases, bolstering confidence in the company's strategy.

Treace Medical Concepts has a diverse ownership structure, with institutional shareholders holding between 40.49% and 84.08% of the stock, insiders owning between 27.42% and 67.47%, and public/individual investors owning between 8.90% and 23.18%. Major institutional owners include CIBC Bancorp USA Inc., Armistice Capital LLC, and BlackRock, Inc. The largest individual shareholder is John T. Treace, the company's Founder, Chairman, and CEO, who owns 25.57 million shares, representing 40.13% of the company.